XU CHERYL
Known title: DirectorCIK: 0001976957
XU CHERYL's purchase track record
How the stock did after each of XU CHERYL's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since January 31, 2024
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-69.2%
3 months: -45.5%
Beat the S&P 500
0%
median -76.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/3/2025 | SXTP | $14K | -51.2% | -66.0% | +14.4% |
| 12/12/2024 | SXTP | $21K | -78.8% | -72.4% | -0.1% |
| 8/27/2024 | SXTP | $9K | -39.9% | -77.1% | +5.9% |
| 1/31/2024 | SXTP | $75K | -13.9% | -47.1% | +14.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SXTP | ▲ Buy | Open Market | 3,000 | $9K | 6/3/2025 | View on chart |
| SXTP | ▲ Buy | Open Market | 2,000 | $6K | 6/3/2025 | View on chart |
| SXTP | ▲ Buy | Open Market | 2,000 | $3K | 12/16/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 1,500 | $2K | 12/13/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 2,500 | $5K | 12/12/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 2,500 | $5K | 12/12/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 5,000 | $9K | 8/27/2024 | View on chart |
| SXTP | ▲ Buy | Option Exercise | 2,000 | $446 | 5/16/2024 | View on chart |
| SXTP | ▲ Buy | Option Exercise | 2,000 | — | 2/1/2024 | View on chart |
| SXTP | ▲ Buy | Open Market | 200,000 | $75K | 1/31/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
SXTP to Release Babesiosis Interim Data and Appear on CNBC
60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.
SXTP to Release Babesiosis Interim Data and Appear on CNBC. 60 Degrees Pharmaceuticals will share interim results from its hospitalized babesiosis study and host a key‑opinion‑leader webinar later this month. The company will also discuss the data on the RedChip Small Stocks, Big Money show broadcast on CNBC and Bloomberg TV. A separate presentation of tafenoquine trial analysis is scheduled for Oct. 6. These events raise the profile of the company's clinical program.